Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • NPPA invites...

    NPPA invites representation and suggestion on Coronary Stents

    Written by Ruby Khatun Khatun Published On 2017-11-14T16:29:41+05:30  |  Updated On 2021-08-14T16:41:28+05:30

    Through a recent notification Government of India, Ministry of Chemicals and Fertilizers, Department of Pharmaceuticals, and National Pharmaceutical Pricing Authority (NPPA) has invited the representations and suggestions with regard to pricing and other related issues from all the domestic stent manufacturers and importers.


    Notice states that 'Coronary Stents' ceiling prices were fixed vide NPPA Notification No.S.0.412(E) dated 13th February 2017 and that is valid for one year. This decision needs to be revisited in the month of January - February 2018.


    NPPA has received some representations with regard to pricing and other related issues.


    All the domestic stent manufacturers and importers are advised to submit any representation and suggestion on this issue positively by December 31, 2017


    Medical Dialogues had earlier reported that NPPA had capped the prices of Stents at Rs 29,600 to bring down the bring down the treatment cost for the benefits of patients.

    Read also: Stent Prices Capped at Rs 29,600, profits slashed

    The impact seems to have not turned out so well as a recent news in ET states that cutting down the stent prices by over 50% by the drug pricing regulators has not lowered the treatment cost as a leading hospital says it has "restructured procedure costs" to compensate for revenue erosion.


    Ashutosh Raghuvanshi, CEO of Narayana Hrudayalaya told ET, "The pricing mechanism in the industry was structurally defective, which means that the profitability was coming only from the implant or the stent and not from the procedure."


    Explaining to ET Raghuvanshi said, "These procedures were not appropriately priced so there was a correction which was required, so we have deconstructed our packages now. To the patient, the treatment cost will still be the same as what it was before the price control."

    Coronary Stents Department of Pharmaceuticals Government of India importers invites manufacturers Ministry of Chemicals and Fertilizers National Pharmaceutical Pricing Authority NPPA representation Stent suggestion 

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      After Abbott, two more Stent makers seek withdrawal of New Gen Stents

      After Abbott, two more Stent makers seek withdrawal of New Gen Stents

      Johnson and Johnson must pay 4 million dollar in punitive damages in latest asbestos cancer trial

      Johnson and Johnson must pay 4 million dollar in punitive damages in latest asbestos cancer trial

      3.36% of about 82,600 drugs samples found to be substandard

      3.36% of about 82,600 drugs samples found to be substandard

      Apollo medical centre in Oman granted hospital status

      Apollo medical centre in Oman granted hospital status

      Aurobindo Pharma receives USFDA approval to manufacture ADHD drug

      Aurobindo Pharma receives USFDA approval to manufacture ADHD drug

      Calcutta HC sets aside Centers decision for strategic sale of Bengal Chemicals

      Calcutta HC sets aside Center's decision for strategic sale of Bengal Chemicals

      Ipca Lab Conferred With the CARE Award

      Ipca Lab Conferred With the CARE Award

      Owners of BLK Hospital, Nanavati Hospital now own 49.7 percent stake in Max Healthcare

      Owners of BLK Hospital, Nanavati Hospital now own 49.7 percent stake in Max Healthcare

      View All

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 27 May 2022 6:45 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier

      This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
      verify here.

      Search only trustworthy HONcode health websites:

      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2020 Minerva Medical Treatment Pvt Ltd

      © 2020 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok
      X
      X